Mitchell S. Bloom

Mr. Bloom's practice is focused on the representation of emerging and public life science companies and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.

His recent client representations include work with:

• Jounce Therapeutics in its $104 million initial public offering, $56 million Series B and $47 million Series A financings
• BeiGene in its $158 million initial public offering and $200 million follow-on public offering
• CRISPR Therapeutics AG in its joint venture with Bayer valued up to $335 million, $38 million additional Series B financing and $56 million initial public offering
• Proteostasis Therapeutics in its $50 million initial public offering and $65 million follow-on public offering
• Quartet Medicine in its $595 million strategic collaboration with Merck
• Ocata Therapeutics in its $379 million sale to Astellas Pharma
• RainDance Technologies in its sale to Bio-Rad Laboratories
• Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 and $125 million follow-on public offerings
• Galapagos NV in its $275 million initial public offering, $337 million follow-on public offering and strategic collaboration with Gilead Sciences valued up to $2 billion
• Neos Therapeutics in its $75 million initial public offering
• Celyad SA in its $100 million initial public offering
• MyoKardia in its $46 million Series B financing and $54 million initial public offering
• Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead Sciences valued up to $1.2 billion, collaborations with Monsanto and Shire Plc and its $43 million Series B financing
• Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A financing, $60 million Series B financing and $70 million initial public offering
• SAGE Therapeutics in its $90 million initial public offering and subsequent $138 million, $150 million and $175 million follow-on public offerings
• Esperion in its $70 million initial public offering and subsequent $97 million and $201 million follow-on public offerings
• Alnylam Pharmaceuticals in its $450 million follow-on public offering and in its strategic alliance and $700 million equity financing with Genzyme
• Magenta Therapeutics in its $50 million Series B and Series A financings
• TCR² Therapeutics in its $44.5 million Series A financing
• Aptinyx in its $65 million Series A financing
• Zafgen in its $96 million initial public offering and subsequent $137 million follow-on public offering
• Inotek Pharmaceuticals in its $60 million initial public offering, $68.9 million follow-on public offering and $50 million follow-on public offering
• DBV Technologies SA in its $92 million initial public offering
• ProQR Therapeutics B.V. in its $97.5 million initial public offering
• Warp Drive Bio in its innovative strategic partnership with Sanofi
• Mevion Medical Systems in connection with its $55 million equity and debt financing and proposed initial public offering $200 million Series F financing
• Relay Therapeutics in its $57 million Series A financing
• Neon Therapeutics in its $70 million Series B financing and $55 million of Series A financing
• Representation of underwriters in connection with public offerings for Reata Pharmaceuticals, Edge Therapeutics, Intrexon Corporation, Roka Biosciences, Tokai Pharmaceuticals, Flexion Therapeutics, NPS Pharmaceuticals, and Regulus Therapeutics